SLC7A7
Basic information
Region (hg38): 14:22773222-22829820
Previous symbols: [ "LPI" ]
Links
Phenotypes
GenCC
Source:
- lysinuric protein intolerance (Strong), mode of inheritance: AR
- lysinuric protein intolerance (Strong), mode of inheritance: AR
- lysinuric protein intolerance (Supportive), mode of inheritance: AR
- lysinuric protein intolerance (Definitive), mode of inheritance: AR
- lysinuric protein intolerance (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Lysinuric protein intolerance | AR | Biochemical | Individuals may manifest with a range of manifestations (eg, developmental delay, failure to thrive with malabsorption, anemia/thrombocytopenia, immunodeficiency, osteoporosis, hemophagocytic lymphohistiocytosis, and pulmonary and renal complications), and dietary/medical therapy (eg, protein restriction, citrulline substitution with use of nitrogen scavengers, lysine supplementation, and carnitine supplementation when necessary) may be beneficial | Allergy/Immunology/Infectious; Biochemical; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Pulmonary; Renal | 4158034; 6076999; 5666624; 5431208; 5553484; 7204568; 3917550; 2732736; 8163273; 8655715; 8892019; 10080183; 9931537; 10080182; 10655553; 10737982; 10451527; 17764084; 18328359; 18716612; 20301535; 21308987; 21716135; 22402328; 22876067; 23358709; 23430827; 23542076; 23772603 |
ClinVar
This is a list of variants' phenotypes submitted to
- Lysinuric protein intolerance (54 variants)
- not provided (3 variants)
- Autoinflammatory syndrome (1 variants)
- SLC7A7-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC7A7 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 223 | 231 | ||||
missense | 182 | 190 | ||||
nonsense | 13 | 13 | 26 | |||
start loss | 4 | |||||
frameshift | 27 | 28 | 56 | |||
inframe indel | 3 | |||||
splice donor/acceptor (+/-2bp) | 11 | 13 | 24 | |||
splice region | 6 | 30 | 1 | 37 | ||
non coding | 15 | 100 | 35 | 150 | ||
Total | 54 | 61 | 203 | 325 | 41 |
Highest pathogenic variant AF is 0.000341
Variants in SLC7A7
This is a list of pathogenic ClinVar variants found in the SLC7A7 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
14-22773283-G-GAGAC | Lysinuric protein intolerance | Uncertain significance (Jun 14, 2016) | ||
14-22773338-G-A | Lysinuric protein intolerance • Autoinflammatory syndrome | Conflicting classifications of pathogenicity (Mar 06, 2019) | ||
14-22773364-C-G | Lysinuric protein intolerance | Uncertain significance (Jan 13, 2018) | ||
14-22773375-C-G | Lysinuric protein intolerance | Uncertain significance (Jan 13, 2018) | ||
14-22773383-C-T | Lysinuric protein intolerance | Uncertain significance (Jan 13, 2018) | ||
14-22773385-C-T | Lysinuric protein intolerance | Uncertain significance (Jan 12, 2018) | ||
14-22773405-T-G | Lysinuric protein intolerance | Uncertain significance (Jan 13, 2018) | ||
14-22773464-CA-C | Likely benign (Sep 16, 2021) | |||
14-22773469-A-C | Lysinuric protein intolerance | Likely benign (Jan 13, 2018) | ||
14-22773476-T-C | Likely benign (Sep 16, 2021) | |||
14-22773496-G-A | Lysinuric protein intolerance | Uncertain significance (Jan 13, 2018) | ||
14-22773594-G-A | Lysinuric protein intolerance | Uncertain significance (Jan 12, 2018) | ||
14-22773602-G-C | not specified | Likely benign (Dec 08, 2016) | ||
14-22773609-TTTAG-T | not specified | Uncertain significance (Aug 10, 2022) | ||
14-22773611-T-C | Lysinuric protein intolerance | Likely benign (Apr 28, 2023) | ||
14-22773613-G-A | Lysinuric protein intolerance | Likely benign (Nov 17, 2023) | ||
14-22773619-T-C | not specified • Lysinuric protein intolerance | Benign (Feb 01, 2024) | ||
14-22773622-G-C | Lysinuric protein intolerance | Likely benign (Aug 06, 2021) | ||
14-22773625-A-G | Lysinuric protein intolerance | Likely benign (Aug 16, 2023) | ||
14-22773626-T-C | Lysinuric protein intolerance | Uncertain significance (Sep 15, 2021) | ||
14-22773628-CCGTTGCTTGGG-C | Lysinuric protein intolerance | Uncertain significance (Mar 27, 2022) | ||
14-22773630-G-A | Lysinuric protein intolerance • Inborn genetic diseases | Uncertain significance (Nov 14, 2023) | ||
14-22773630-G-T | Lysinuric protein intolerance | Likely benign (Oct 09, 2023) | ||
14-22773631-T-C | Lysinuric protein intolerance | Likely benign (Dec 03, 2019) | ||
14-22773635-T-A | Inborn genetic diseases | Uncertain significance (Jun 28, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SLC7A7 | protein_coding | protein_coding | ENST00000397532 | 9 | 56599 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
7.95e-7 | 0.916 | 125576 | 0 | 171 | 125747 | 0.000680 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.485 | 254 | 277 | 0.918 | 0.0000149 | 3298 |
Missense in Polyphen | 106 | 106.77 | 0.99275 | 1315 | ||
Synonymous | -0.316 | 114 | 110 | 1.04 | 0.00000619 | 1067 |
Loss of Function | 1.71 | 13 | 21.6 | 0.603 | 0.00000117 | 253 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000633 | 0.000633 |
Ashkenazi Jewish | 0.000198 | 0.000198 |
East Asian | 0.000598 | 0.000598 |
Finnish | 0.00462 | 0.00463 |
European (Non-Finnish) | 0.000308 | 0.000308 |
Middle Eastern | 0.000598 | 0.000598 |
South Asian | 0.000294 | 0.000261 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the sodium-independent uptake of dibasic amino acids and sodium-dependent uptake of some neutral amino acids. Requires coexpression with SLC3A2/4F2hc to mediate the uptake of arginine, leucine and glutamine. Plays a role in nitric oxide synthesis in human umbilical vein endothelial cells (HUVECs) via transport of L-arginine. Involved in the transport of L- arginine in monocytes. {ECO:0000269|PubMed:14603368, ECO:0000269|PubMed:15280038, ECO:0000269|PubMed:17329401, ECO:0000269|PubMed:9829974, ECO:0000269|PubMed:9878049}.;
- Disease
- DISEASE: Lysinuric protein intolerance (LPI) [MIM:222700]: A metabolic disorder characterized by increased renal excretion of cationic amino acid (CAA), reduced CAA absorption from intestine, and orotic aciduria. On a normal diet, LPI patients present poor feeding, vomiting, diarrhea, episodes of hyperammoniaemic coma and growth retardation. Hepatosplenomegaly, osteoporosis and a life- threatening pulmonary involvement (alveolar proteinosis) are also seen. Biochemically LPI is characterized by defective transport of dibasic amino acids at the basolateral membrane of epithelial cells in kidney and intestine. {ECO:0000269|PubMed:10080182, ECO:0000269|PubMed:10631139, ECO:0000269|PubMed:10655553, ECO:0000269|PubMed:12402335, ECO:0000269|PubMed:15756301, ECO:0000269|PubMed:15776427, ECO:0000269|PubMed:17764084, ECO:0000269|PubMed:9829974}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Protein digestion and absorption - Homo sapiens (human);Polythiazide Action Pathway;Methyclothiazide Action Pathway;Bumetanide Action Pathway;Spironolactone Action Pathway;Eplerenone Action Pathway;Triamterene Action Pathway;Amiloride Action Pathway;Ethacrynic Acid Action Pathway;Quinethazone Action Pathway;Bendroflumethiazide Action Pathway;Chlorthalidone Action Pathway;Trichlormethiazide Action Pathway;Iminoglycinuria;Lysinuric Protein Intolerance;Blue diaper syndrome;Lysinuric protein intolerance (LPI);Glutaminolysis and Cancer;Cystinuria;Indapamide Action Pathway;Furosemide Action Pathway;Torsemide Action Pathway;Hartnup Disorder;Glucose Transporter Defect (SGLT2);Kidney Function;Glucose Transporter Defect (SGLT2);Metolazone Action Pathway;Hydrochlorothiazide Action Pathway;Cyclothiazide Action Pathway;Hydroflumethiazide Action Pathway;Chlorothiazide Action Pathway;TYROBP Causal Network;Amino acid transport across the plasma membrane;Amino acid and oligopeptide SLC transporters;Transport of inorganic cations/anions and amino acids/oligopeptides;SLC-mediated transmembrane transport;Transport of small molecules;Cell surface interactions at the vascular wall;Hemostasis;Basigin interactions
(Consensus)
Recessive Scores
- pRec
- 0.163
Intolerance Scores
- loftool
- 0.114
- rvis_EVS
- -0.71
- rvis_percentile_EVS
- 14.57
Haploinsufficiency Scores
- pHI
- 0.350
- hipred
- N
- hipred_score
- 0.199
- ghis
- 0.582
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.879
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Slc7a7
- Phenotype
- homeostasis/metabolism phenotype; muscle phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; embryo phenotype; renal/urinary system phenotype; skeleton phenotype; immune system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Zebrafish Information Network
- Gene name
- slc7a7
- Affected structure
- macrophage
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- regulation of arginine metabolic process;amino acid transmembrane transport;cellular amino acid metabolic process;leukocyte migration;protein-containing complex assembly;L-alpha-amino acid transmembrane transport;basic amino acid transmembrane transport
- Cellular component
- plasma membrane;integral component of plasma membrane;basolateral plasma membrane
- Molecular function
- basic amino acid transmembrane transporter activity;L-amino acid transmembrane transporter activity